


## YHO-13351 free base

|                           |   |       |          |
|---------------------------|---|-------|----------|
| <b>Cat. No.:</b>          | HY-12758A   |       |          |
| <b>CAS No.:</b>           | 912288-64-3   |       |          |
| <b>Molecular Formula:</b> | C <sub>26</sub> H <sub>33</sub> N <sub>3</sub> O <sub>4</sub> S |       |          |
| <b>Molecular Weight:</b>  | 483.62  |       |          |
| <b>Target:</b>            | BCRP  |       |          |
| <b>Pathway:</b>           | Membrane Transporter/Ion Channel                                |       |          |
| <b>Storage:</b>           | Powder  | -20°C | 3 years  |
|                           |   | 4°C   | 2 years  |
|                           | In solvent  | -80°C | 6 months |
|                           |   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (206.77 mM; Need ultrasonic)

**Caution: Product has not been fully validated for medical applications. For research use only.**

| Solvent                   | Mass   |           |            |
|---------------------------|--|-----------|------------|
|                           | 1 mg   | 5 mg      | 10 mg      |
| Concentration             | Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA |           |            |
| Preparing Stock Solutions | 1 mM   | 2.0677 mL | 10.3387 mL |
|                           | 5 mM   | 0.4135 mL | 2.0677 mL  |
|                           | 10 mM  | 0.2068 mL | 1.0339 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

YHO-13351 free base is the prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.

### REFERENCES

- [1]. Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.
- [2]. Shishido Y, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013 Apr;33(4):1379-86.